| Statistical analysis
A sample size was calculated based on the TDD and the number of insulin injections. It was found that a sample size of 16 patients would be sufficient to detect a reduction in TDD to 50% of the dosage before adding Lira, assuming a standard deviation of 8, α = 0.05 and power of 85%. Additionally, we determined that the enrolment of six patients would be sufficient to detect a reduction in the number of insulin injections from 4 to 2 times per day, assuming a standard deviation of 1.2, α = 0.05 and power of 85%. Therefore, we aimed to include 20 patients in this study based on those two criteria. Data are presented as median values and interquartile ranges (IQRs). A Wilcoxon test was used to test the differences between the two indicated groups. The numbers of insulin injections were compared using Fisher's exact test. For both analyses, P < 0.05 was considered statistically significant. All statistical analyses were conducted using STATA software (StataCorp LLC, College Station, TX).
| RE SULTS

| Baseline characteristics
A total of 20 patients with T2D participated in this study. The participant characteristics are presented in Table 1 
| Changes in the metabolic parameters after the addition of Lira to insulin therapy
Six months after Lira was added, the TDD significantly decreased from Table 2 ). These data indicate that Lira improves not only HbA1c levels, but also the degree of blood glucose fluctuations, even after a decrease in the dosage of insulin injections and cessation of sulfonylurea in elderly T2D patients.
| Favourable effects of Lira on glucose fluctuation
| Safety of the combination therapy using Lira and insulin
After the addition of Lira, the dosages of oral hypoglycaemic agents and insulin were appropriately decreased, targeted at the levels of fasting or pre-meal blood glucose (100-140 mg/dL). Consequently, there were no hypoglycaemic events, hypoglycaemic symptoms and/or self-monitoring blood glucose levels <70 mg/dL not only before but also during the administration of Lira. Furthermore, in the results of the CGM analysis, glucose levels below 70 mg/dL
were not detected at all during the administration of Lira (Table 2 ).
In terms of the adverse events related to gastrointestinal disor- 
| D ISCUSS I ON
The present study demonstrated that the administration of Lira could safely improve glycaemic control in elderly patients, in spite of the decrease in the insulin dose and number of insulin injections. A previous study showed that GLP-1RA in combination with basal insulin therapy was an effective treatment option with respect to weight loss and fewer hypoglycaemic events. 10 Our study focused on T2D patients older than 65 years, for the evaluation of the efficacy and safety of the combination therapy using GLP-1RA and insulin, since hypoglycaemic events related to diabetes treatment are relatively common in older patients. 11 In particular, multiple insulin injections and sulfonylurea administration are associated with a risk for hypoglycaemia. Throughout the present study, no hypoglycaemic events were detected even in the data from CGM, suggesting that the addition of the GLP-1RA, Lira, to insulin therapy could safely improve glycaemic control even in elderly patients, if the dosages of insulin and oral hypoglycaemic agents are appropriately adjusted.
As demonstrated in the present study, the decreased number of insulin injections may improve the quality of life in elderly T2D
patients. Furthermore, the formulation of a simplified therapeutic option for diabetes may be beneficial in terms of treatment adherence for elderly individuals, particularly those who require social support. In addition, the TDDs were decreased 52.9%, which was a greater reduction than that found in a previous study. 12 GLP-1RAs
could reduce fasting blood glucose through the inhibition of glucose-dependent glucagon secretion from pancreatic alpha cells and gluconeogenesis in the liver and reduce postprandial blood glucose by delaying gastric emptying. 13 Those effects of GLP-1RAs may be associated with the reduction in TDD. The reduction in the degree of fluctuation in glucose levels, as shown in the CGM analysis results, may also improve the quality of life and treatment adherence among elderly T2D patients and may be helpful for medical staff members who provide support to elderly people with diabetes. In our CGM analyses, the frequencies of hyperglycaemia were significantly decreased. The reduction in both fasting and postprandial blood glucose by Lira might contribute to the reduction in hyperglycaemia. 14 The addition of Lira to insulin therapy led to reduced BWs in our study. This reduction may have been achieved because of the effects of Lira itself and reductions in the doses of insulin or sulfonylurea. Insulin therapy induces a certain amount of BW gain in T2D patients, 15 whereas GLP-1 RAs might reduce BW by inducing satiety in the hypothalamus. 13, 16 In our study, the reduction in TDD may be partially responsible for BW reduction. The effects of Lira on weight loss are also associated with delays in gastric emptying. 17 It has been demonstrated that the administration of Lira can reduce the proportion of visceral adipose tissue. 18 With respect to weight loss for the elderly, attention should be paid to disuse syndrome which leads to a loss of skeletal muscle volume. Among our study's participants, the daily activity was not impaired, perhaps because they were originally relatively overweight. Moreover, a recent study showed that Lira may be beneficial for cardiovascular and renal function. 19, 20 The present study had certain limitations. Firstly, it had a singlearm design, with a relatively low number of participants and short period (6 months) of observation. In addition, although our target glucose level was 100-140 mg/dL before each meal, we did not use any strict algorithm for glucose adjustment. Additionally, the dosage of insulin was adjusted according to the glucose levels during the study period. Therefore, randomized studies with a higher number of participants, longer periods, and strict algorithms for the adjustment of insulin and oral hypoglycaemic agents should be considered in future.
In conclusion, the addition of Lira to insulin therapy improved glycaemic and BW control, without increasing the number of hypoglycaemic events in elderly T2D patients. The reduction in the number of insulin injections may be beneficial for the elderly individuals, especially those who require social support.
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